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Alloimmunization to granulocyte-speciﬁc antigens can occur during pregnancy. Maternal antibodies of IgG class can cross the
placenta to result in alloimmune neonatal neutropenia. Antibodies to human neutrophil antigens anti-HNA-1a, HNA-1b, and
HNA-2ahavebeenmostcommonlyreportedtocausealloimmuneneonatalneutropenia.IsoantibodiestoFcgammaRIIIb(CD16)
if mother is a HNA-null phenotype are rarely involved in neonatal neutropenia. We report on a case of severe neutropenia (440
neutrophils/μL) due to anti-Fc gamma RIIIb (CD16) isoimmunization. On day 14 severe omphalitis developed, which was treated
for 7 days by an antibiotic (ceftriaxone in a dose of 80mg/kg/d) according to umbilical swab ﬁnding. Omphalitis persisted for 10
days in spite of antibiotic therapy and only resolved upon the introduction of rhG-CSF therapy. Therapy with rh-GCSF proved
eﬃcient and led to neutrophil count increase to 1970/μL and cure of omphalitis. However, therapeutic eﬀect on granulocyte count
was of transient nature, as granulocyte count fell to 760n/μL on day 4 of therapy discontinuation. Neutropenia persisted for 2
months. The newborn was discharged from the hospital on day 26 with normal clinical status with clinical and laboratory control
examinations at 2-week intervals. No additional infections were observed during the course of neutropenia.
Copyright © 2009 Maja Tomicic et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Alloimmune neonatal neutropenia (ANN) is an uncommon
but potentially life-threatening disorder of the neonate [1].
TheincidenceofANNhasbeenestimatedto1per 1000–6000
live births [2]. ANN is the result of maternal alloimmuniza-
tiontogranulocyteantigens.Thepassivetransferofmaternal
neutrophil-speciﬁc antibodies and subsequent sensitization
of fetal neutrophils can result in severe neutropenia of the
neonate [2].
Antibodies to granulocyte-speciﬁc antigens HNA-1a and
HNA-1b have been most commonly reported to cause ANN.
Anti-HNA-2a and antibodies to Fc gamma RIIIb (CD16),
if mother is a HNA-1-null phenotype are rarely involved in
neonatal neutropenia [3–5].
ANN should be suspected in a newborn with isolated
neutropenia (<1500 cells/μL) [4, 5].
The course of pregnancy is uneventful, and mother has
normal granulocyte count and no clinical history of frequent
bacterial infections [2].
The clinical course is usually self-limiting with only
mild infection; however, in severe cases complicated with
bacterial sepsis it is a potentially life-threatening disorder
[3].
Demonstration of alloantibodies against granulocyte-
speciﬁcantigensharedbyneonatalandpaternalgranulocytes
in maternal serum is essential in the diagnosis of ANN.
Human neutrophil antigen (HNA) genotyping of mother
and father can be useful in supporting serology results
[6–11].2 Case Reports in Medicine
Table 1: Results of serologic testing.
GIFT IT GIFT DT GAT IT MAIGA CD16 Fc
gamma RIIIb
MAIGA
CD177
MAIGA
CD11 a/11 b
MAIGA Beta-
2microglobulin
Maternal
Serum pos pos pos, anti-HNA-1
pan-reactive neg neg pos,
anti-HLA-class I
Granulocytes neg
Newborn
Serum pos pos pos, anti-HNA-1
pan-reactive neg neg pos,
anti-HLA-class I
Granulocytes pos
GIFT =granulocyteimmunoﬂuorescencetest,GAT =granulocyteagglutinationtest,MAIGA =monoclonalantibodyimmobilizationofgranulocyteantigens,
IT = indirect test, DT = direct test, Fc gamma RIIIb = Receptor Fc gamma IIIb, pos = positive, neg = negative, HNA = human neutrophil antigen, and HLA =
human leukocyte antigen.
The treatment usually includes antibiotics, intravenous
gamma globulins, and in severe cases of ANN complicated
with bacterial sepsis therapy with rhG-CSF is indicated,
however, with a variable success [12–15].
The issue of the choice and eﬃcacy of speciﬁc therapy to
increase the blood neutrophil count in the management of
ANN is not fully deﬁned.
2.CaseReport
A male newborn, birth weight 3540g, was born from second,
uncomplicated pregnancy, to a healthy 29-year-old mother,
in 40th week of gestation. Mother had a normal neutrophil
count. First borne child was healthy. Mother’s sister is of the
same HNA-1-null genotype, delivered two healthy children.
Severe neutropenia (440 neutrophils/μL) with normal
ﬁndings of other laboratory tests was detected on the ﬁrst
day of the newborn’s life.
On day 14 severe omphalitis developed, which was
treated for 7 days by an antibiotic (ceftriaxone in a dose of
80mg/kg/d) according to umbilical swab ﬁnding.
Upon making the diagnosis of neonatal isoimmune neu-
tropenia due to anti-Fc gamma RIIIIb (CD16) pan-reactive
antibodies, therapy with rh-GCSF from day 19 to day 23
(Neupogeninadoseof5μg/kg/d)wasintroduced(Figure 1).
Therapywithrh-GCSFprovedeﬃcientandledtoneutrophil
count increase to 1970/μL and cure of omphalitis. However,
therapeutic eﬀect on granulocyte count was of transient
nature, as granulocyte count fell to 760 neutrophils/μLo n
day 4 of therapy discontinuation. Neutropenia persisted for
2 months (Figure 1). The newborn was discharged from the
hospital on day 26 with normal clinical status with clinical
and laboratory control examinations at 2-week intervals. No
additional infections were observed during the course of
neutropenia.
3.Serology
Serologic studies of the mother’s and newborn’s sera
included granulocyte immunoﬂuorescence tests, direct and
indirect (GIFT-DT, IT), granulocyte agglutination test
(GAT), and monoclonal antibody immobilization of granu-
locyte antigens (MAIGAs) for granulocyte antibody screen-
ing and identiﬁcation [6–11].
IgG class antigranulocyte antibodies were detected by
GIFT in the maternal and neonatal sera. Results of serologic
testing are summarized in Table 1 showing anti-CD 16 pan-
reactive antibodies in the maternal and newborn’s sera.
Antibody identiﬁcation is deﬁnitely veriﬁed by deter-
mination of maternal, paternal, and neonatal HNA by
polymerase chain reaction-sequence-speciﬁc primers (PCR-
SSP) [10, 11]. Following primers were used:
HNA-1A 5-CAGTGGTTTCACAATGTGAA -3
HNA-1AR 5-ATGGACTTCTAGCTGCAC -3
HNA-1-B 5-CAATGGTACAGCGTGCTT -3
HNA-1BR 5-ACTGTCGTTGACTGTGTCAG- 3
HNA-1C 5- AAGATCTCCCAAAGGCTGTG - 3
HNA-1CR 5- ACTGTCGTTGACTGTGTCAT -3
HGH-1 5-CAGTGCCTTCCCAACCATTCCCT-
TA-3 
HGH-2 5-ATCCACTCACGGATTTCTGTTGT-
GTTTC -3
The presence of 439-bp fragment of the human growth hor-
mone gene indicated that ampliﬁcation took place properly,
and no nonspeciﬁc reactions were observed.
HNA genotyping of the mother showed Fc gamma RIIIb
deﬁciency (HNA-1a=,1 b =,1 c =). The newborn and father
were genotyped as HNA-1a=,1 b + ,1 c = conﬁrming the
diagnosis of isoimmune neonatal neutropenia. Results are
shown on Figure 2.
4. Discussion
W er e p o r to nac a s eo fs e v e r en e o n a t a ln e u t r o p e n i ad u e
to anti-Fc gamma RIIIb (CD16) isommunization in the
child born from the second uneventful pregnancy to healthy
mother.
Several cases of immune neonatal neutropenia caused by
anti-Fc gamma RIIIb isoantibodies have been described inCase Reports in Medicine 3
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Figure 1: The neonate’s neutrophil count pattern and hr-G-CSF
therapy course.
literature [4, 16–19]. Fromont et al. report on the presence
of iso-anti-CD-16 antibodies in one of ﬁve individuals with
FcgammaRIIIbdeﬁciency(threeofthempregnantwomen),
all of them being healthy [17]. Haas et al. analyzed history
data of 21 donors with Fc gamma RIIIb deﬁciency identiﬁed
in 14 unrelated families. Recurrent bacterial infections were
recorded in 3/21 subjects, whereas others had never had any
serious bacterial infection [4].
In the case presented, a severe form of omphalitis was
observed on postnatal day 14 and persisted for 10 days of
antibiotictherapyintroduction,asindicatedbytheantibiotic
sensitivity report followed by rhG-CSF therapy. Omphalitis
persisted in spite of antibiotic therapy and only resolved
upon the introduction of rhG-CSF therapy.
The issue of the choice and eﬃcacy of speciﬁc therapy
to increase the blood neutrophil count in the management
of ANN is not fully deﬁned [20]. The eﬀect of prophy-
lactic antibiotic therapy, intravenous immunoglobulin, and
recombinant human granulocyte colony-stimulating factor
(rh-GCSF) is variable and may prove useful in some cases
[20, 21].
According to literature data, clinical experience with rh-
GCSF use is highly favourable but mostly referring to the
management of neutropenia following bone marrow and
stem cell transplantation neonatal sepsis and autoimmune
neutropenia [22, 23]. Experience with rh-GCSF in the
treatment of ANN is quite limited, and the eﬀect of rh-GCSF
on developing tissues of the neonate is unknown [24, 25]. In
the majority of ANN cases, the use of rh-GCSF resulted in a
very rapid and steady neutrophil count increase [26].
In our patient, therapy with rh-GCSF proved eﬃcient
and led to an increase in neutrophil count and resolution
of omphalitis. However, therapeutic eﬀect on granulocyte
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Figure 2: HNA-1 genotyping by PCR-SSP method, Electrophoresis
of HNA-1 allele PCR products on 1.5% agarose gel for three
subjects and three HNA alleles 1a, 1b, and 1c. Mother: lanes 1, 2,
and 3, genotype HNA-1a negative, 1b negative, 1c negative; lane
4 molecular marker 100bp; Father: lanes 5, 6, and 7, genotype
is HNA-1a negative, 1b positive, 1c negative; Newborn: lanes 8,
9, and 10, genotype HNA-1a negative, 1b positive, 1c negative;
human growth hormone (HGH) gene fragment of 439bp used
as internal positive control; the ampliﬁed HNA-1b allele positive
product 155bp.
count was transient, since granulocyte count showed a
decline on day 4 of therapy discontinuation.
The child was discharged for home care with clinical
and laboratory control examinations at 2-week intervals. No
further bacterial infections were observed during the 8-week
period of neutropenia. Therefore, we decided to follow up
thecourseofthediseaseandtoreintroducerh-GCSFtherapy
in case of severe bacterial infection or sepsis development.
We believe that in case of a mild clinical course of the
disease, a neonate beneﬁts more from being discharged for
home care than from insisting on normal neutrophil count
achievement associated with prolonged hospital stay and
potential exposure to hospital infections. Yet, we are fully
aware of the risk of severe and protracted neutropenia. This
case report may hopefully present a step forward to elucidate
the issue.
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